



Hematology/Oncology Pharmacy Association (HOPA) – Patient Outreach Committee

Guidelines and Expectations of the Patient Advisory Panel

Patient Advisory Mission Statement

To provide patients who have been impacted by cancer and blood diseases a platform to influence the overall mission* of the Hematology/Oncology Pharmacy Association.

Patient Advisory Vision Statement

The Patient Advisory Panel will use their experiences and expertise to provide feedback and guidance on programs and initiatives of the Hematology/Oncology Pharmacy Association.

Duties and Responsibilities

- Work cooperatively and respectfully with members of the Patient Advisory Panel.
- Provide responsive and ongoing feedback with individuals and committees within HOPA on content, which includes, but is not limited to, programming, initiatives, policies, and publications.
- Identify and promote ways to advance the relationship between hematology/oncology pharmacists and patients.
- Be willing to attend advocacy events such as HOPA Hill Day and share experiences publicly to promote and advocate for the value of hematology/oncology pharmacists on patient care issues. Participation in advocacy events is not mandatory.
- When necessary, assist HOPA and the Patient Outreach Committee in identifying individuals to be members of the Patient Advisory Panel.

Terms:

The term of service is at least two (2) years. Terms will begin on Aug 1st and end on July 30th in alignment with the Patient Outreach Committee timeline. Terms may be renewed once (max 4 years) if desired in order to promote panel continuity.

*Note: The start date for the inaugural panel is subject to change.

Although not expected, a member can be suspended or removed from the Patient Advisory Panel by any member of the HOPA Board or the Patient Outreach Committee Panel Liaison for behavior that reflects poorly on the HOPA organization.

New Members:

5-10 members will serve on the Patient Advisory Panel. Efforts will be made for the panel to have a diverse group of members including patients of all ages, stages in therapy (active diagnosis, survivorship, etc.), and across all cancer/disease types. The Patient Outreach Committee will have permission to reevaluate annually the total number of members on the panel. Additionally, if panel membership declines to less than 5 members, the Patient Outreach Committee will immediately have the ability to interview and add new members to meet the panel's duties and responsibilities. Interested candidates should complete an application, which will be discussed and voted upon by members of the Patient Outreach Committee.

Oversight:

The Patient Outreach Committee will provide continued oversight and guidance to the Patient Advisory Panel. The Patient Outreach Committee will convene the Patient Advisory Panel when there is a request made by a HOPA committee for assistance and direction. The Patient Outreach Committee may make individual requests to panel members when a request is made for expertise or experience on a specific subject.

Use of Information:

In the course of participating in the Patient Advisory Panel, patients will reveal sensitive information about themselves, including health-related information (such as Patient Health Information (PHI)). This information must be treated respectfully. It is not permitted to be discussed with people who do not have a HOPA-related need to know the information, including your friends and family members. Respectful treatment of patient disclosures will help assure the success of the Patient Advisory Panel.

For further questions, please contact Brooke Boring, HOPA's Health Policy and Advocacy Manager, at bboring@hoparx.org.

*Hematology/Oncology Pharmacy Association's Mission: Support pharmacy practitioners and promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer.